How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

404 results for

Quinupristin-Dalfopristin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Enterococcal Infection (Diagnosis)

therapy, and management of complications: a statement for healthcare professionals. Circulation . 2005 Jun 14. 111(23):e394-434. . . Bell EA. Quinupristin/dalfopristin: An interesting new antibiotics period. Infect Dis Child . 2000. 13(3):53. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis . 2005. 191:588-595. . . Furuno JP, Perencevich EN, Johnson JA, et al. Methicillin-resistant

2014 eMedicine Pediatrics

82. Staphylococcal Infections (Diagnosis)

of staphylococcal infections (listed alphabetically, not necessarily in order of preference): Cefazolin Ceftaroline Cefuroxime Clindamycin Dalbavancin Daptomycin Dicloxacillin Doxycycline Linezolid Minocycline Nafcillin Oritavancin Quinupristin/dalfopristin Tedizolid Telavancin Tigecycline Trimethoprim-sulfamethoxazole Vancomycin Delafloxacin Surgery Abscesses must be drained and/or debrided. Infections involving a prosthetic joint usually require removal of the prosthesis. Other infections involving

2014 eMedicine.com

83. Mycobacterium Marinum (Diagnosis)

Dermatol . 2005 Apr. 152(4):727-34. . Bråbäck M, Riesbeck K, Forsgren A. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones. Antimicrob Agents Chemother . 2002 Apr. 46(4):1114-6. . Edelstein H. Mycobacterium marinum skin infections. Report of 31 cases and review of the literature. Arch Intern Med . 1994 Jun 27. 154

2014 eMedicine.com

84. Enterococcal Infections (Diagnosis)

result in synergistic bactericidal activity against enterococci. The acquisition of vancomycin resistance by enterococci has seriously affected the treatment and infection control of these organisms. VRE, particularly E faecium strains, are frequently resistant to all antibiotics that are effective treatment for vancomycin-susceptible enterococci, which leaves clinicians treating VRE infections with limited therapeutic options. Newer antibiotics (eg, quinupristin-dalfopristin, linezolid, daptomycin (...) , tigecycline) with activity against many VRE strains have improved this situation, but resistance to these agents has already been described. A mutation (G2576U) in the domain V of the 23S rRNA is responsible for linezolid resistance, [ ] whereas resistance to quinupristin-dalfopristin may be the result of several mechanisms: modification of enzymes, active efflux, and target modification. Resistance of E faecalis and E faecium to daptomycin, a newer cyclic lipopeptide antibiotic that acts on the bacterial

2014 eMedicine.com

85. Streptococcus Group D Infections (Treatment)

, or the perils of revised nomenclature in bacteriology. Clin Infect Dis . 2005 Apr 1. 40(7):1070-1. . Ruoff KL, Miller SI, Garner CV, et al. Bacteremia with Streptococcus bovis and Streptococcus salivarius: clinical correlates of more accurate identification of isolates. J Clin Microbiol . 1989 Feb. 27(2):305-8. . Mouton JW, Endtz HP, den Hollander JG, et al. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. J

2014 eMedicine.com

86. Cellulitis (Treatment)

IV q6-8h Meropenem 1 g IV q8h Ertapenem 1 g IV qd Cefotaxime 2 g IV q6h plus metronidazole 500 mg IV q6h or clindamycin 600-900 mg/kg IV q8h The following are first-line treatments in managing adult S aureus (MSSA) infections [ ] : Nafcillin (for patients with severe penicillin hypersensitivity: vancomycin, linezolid, quinupristin-dalfopristin, or daptomycin; add an appropriate agent in the presence of [or if there is a suspicion of] staphylococcal infection) or oxacillin 1-2 IV q4h Cefazolin 1 g (...) IV q8h Clindamycin 600-900 mg/kg IV q8h (may have cross-resistance and emergence resistance in erythromycin-resistant strains; induces resistance in MRSA) First-line agents in managing severe adult streptococcal infection are penicillin 2-4 MU IV every 4-6 hours plus clindamycin 600-900 mg/kg IV every 8 hours. [ ] For patients with severe penicillin hypersensitivity, use vancomycin, linezolid, quinupristin-dalfopristin, or daptomycin. Add an appropriate agent if a staphylococcal infection

2014 eMedicine.com

87. Cellulitis (Treatment)

IV q6-8h Meropenem 1 g IV q8h Ertapenem 1 g IV qd Cefotaxime 2 g IV q6h plus metronidazole 500 mg IV q6h or clindamycin 600-900 mg/kg IV q8h The following are first-line treatments in managing adult S aureus (MSSA) infections [ ] : Nafcillin (for patients with severe penicillin hypersensitivity: vancomycin, linezolid, quinupristin-dalfopristin, or daptomycin; add an appropriate agent in the presence of [or if there is a suspicion of] staphylococcal infection) or oxacillin 1-2 IV q4h Cefazolin 1 g (...) IV q8h Clindamycin 600-900 mg/kg IV q8h (may have cross-resistance and emergence resistance in erythromycin-resistant strains; induces resistance in MRSA) First-line agents in managing severe adult streptococcal infection are penicillin 2-4 MU IV every 4-6 hours plus clindamycin 600-900 mg/kg IV every 8 hours. [ ] For patients with severe penicillin hypersensitivity, use vancomycin, linezolid, quinupristin-dalfopristin, or daptomycin. Add an appropriate agent if a staphylococcal infection

2014 eMedicine.com

88. Infective Endocarditis (Treatment)

to achieve synergy against enterococci, but the practice of administering gentamicin for 5 days in the treatment of S aureus IV drug abuse (IVDA) IE should be questioned. Vancomycin-resistant isolates of Enterococcus faecium and Enterococcus faecalis (ie, vancomycin-resistant enterococci [VRE]) produce some of the most challenging nosocomial infections. Presently, no therapy has been proven highly effective for IE caused by strains of VRE. Quinupristin/dalfopristin (ie, Synercid) may suppress E faecium

2014 eMedicine.com

89. Peptostreptococcus Infection (Treatment)

with aerobic organisms, choose antimicrobial agents that treat both types of pathogens, taking into consideration their aerobic and anaerobic antibacterial spectrum and their availability in oral or parenteral form. [ , ] Penicillin G is most effective for treating anaerobic gram-positive cocci and microaerophilic streptococci. Other effective agents include other penicillins, cephalosporins, chloramphenicol, clindamycin, vancomycin, telithromycin, linezolid, quinupristin/dalfopristin, and carbapenems

2014 eMedicine.com

90. Staphylococcal Infections (Overview)

of staphylococcal infections (listed alphabetically, not necessarily in order of preference): Cefazolin Ceftaroline Cefuroxime Clindamycin Dalbavancin Daptomycin Dicloxacillin Doxycycline Linezolid Minocycline Nafcillin Oritavancin Quinupristin/dalfopristin Tedizolid Telavancin Tigecycline Trimethoprim-sulfamethoxazole Vancomycin Delafloxacin Surgery Abscesses must be drained and/or debrided. Infections involving a prosthetic joint usually require removal of the prosthesis. Other infections involving

2014 eMedicine.com

91. Streptococcus Group D Infections (Overview)

with Streptococcus bovis and Streptococcus salivarius: clinical correlates of more accurate identification of isolates. J Clin Microbiol . 1989 Feb. 27(2):305-8. . Mouton JW, Endtz HP, den Hollander JG, et al. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. J Antimicrob Chemother . 1997 May. 39 Suppl A:75-80. . Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, et al. Infective endocarditis

2014 eMedicine.com

92. Mycobacterium Marinum (Overview)

Dermatol . 2005 Apr. 152(4):727-34. . Bråbäck M, Riesbeck K, Forsgren A. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones. Antimicrob Agents Chemother . 2002 Apr. 46(4):1114-6. . Edelstein H. Mycobacterium marinum skin infections. Report of 31 cases and review of the literature. Arch Intern Med . 1994 Jun 27. 154

2014 eMedicine.com

93. Enterococcal Infections (Treatment)

of treatment for endocarditis, a 6-week rather than 4-week course of therapy is recommended. Combination therapy is also recommended to treat enterococcal meningitis, usually for at least 2-3 weeks. Intravenous linezolid or intravenous plus intraventricular quinupristin-dalfopristin have also been used to successfully treat meningitis. The emergence of enterococcal strains with multidrug-resistant determinants has significantly complicated the management of enterococcal infections. Vancomycin should (...) imipenem-cilastatin or ampicillin plus ceftriaxone may be considered. [ ] For E faecium infection, either linezolid or daptomycin may be effective, and quinupristin-dalfopristin or tigecycline could be considered. Surgical approaches may be necessary (see Surgical Care). For VRE infections, base the treatment on infection severity and in vitro susceptibility of the strain to other antibiotics. Uncomplicated UTIs have been treated successfully with nitrofurantoin. Isolates that remain relatively

2014 eMedicine.com

94. Mycobacterium Marinum (Treatment)

arthritis and osteomyelitis. Br J Rheumatol . 1997 Nov. 36(11):1207-9. . Bartralot R, Garcia-Patos V, Sitjas D, et al. Clinical patterns of cutaneous nontuberculous mycobacterial infections. Br J Dermatol . 2005 Apr. 152(4):727-34. . Bråbäck M, Riesbeck K, Forsgren A. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones

2014 eMedicine.com

95. Mycobacterium Marinum (Follow-up)

of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin, linezolid, moxifloxacin, telithromycin, and quinupristin-dalfopristin (Synercid) compared to its susceptibilities to reference macrolides and quinolones. Antimicrob Agents Chemother . 2002 Apr. 46(4):1114-6. . Edelstein H. Mycobacterium marinum skin infections. Report of 31 cases and review of the literature. Arch Intern Med . 1994 Jun 27. 154(12):1359-64. . El-Etr SH, Subbian S, Cirillo SL, et al. Identification of two Mycobacterium marinum

2014 eMedicine.com

96. Infective Endocarditis (Follow-up)

to achieve synergy against enterococci, but the practice of administering gentamicin for 5 days in the treatment of S aureus IV drug abuse (IVDA) IE should be questioned. Vancomycin-resistant isolates of Enterococcus faecium and Enterococcus faecalis (ie, vancomycin-resistant enterococci [VRE]) produce some of the most challenging nosocomial infections. Presently, no therapy has been proven highly effective for IE caused by strains of VRE. Quinupristin/dalfopristin (ie, Synercid) may suppress E faecium

2014 eMedicine.com

97. Enterococcal Infections (Follow-up)

of treatment for endocarditis, a 6-week rather than 4-week course of therapy is recommended. Combination therapy is also recommended to treat enterococcal meningitis, usually for at least 2-3 weeks. Intravenous linezolid or intravenous plus intraventricular quinupristin-dalfopristin have also been used to successfully treat meningitis. The emergence of enterococcal strains with multidrug-resistant determinants has significantly complicated the management of enterococcal infections. Vancomycin should (...) imipenem-cilastatin or ampicillin plus ceftriaxone may be considered. [ ] For E faecium infection, either linezolid or daptomycin may be effective, and quinupristin-dalfopristin or tigecycline could be considered. Surgical approaches may be necessary (see Surgical Care). For VRE infections, base the treatment on infection severity and in vitro susceptibility of the strain to other antibiotics. Uncomplicated UTIs have been treated successfully with nitrofurantoin. Isolates that remain relatively

2014 eMedicine.com

98. Streptococcus Group D Infections (Follow-up)

. Saunders; 2007. 1713. van't Wout JW, Bijlmer HA. Bacteremia due to Streptococcus gallolyticus, or the perils of revised nomenclature in bacteriology. Clin Infect Dis . 2005 Apr 1. 40(7):1070-1. . Ruoff KL, Miller SI, Garner CV, et al. Bacteremia with Streptococcus bovis and Streptococcus salivarius: clinical correlates of more accurate identification of isolates. J Clin Microbiol . 1989 Feb. 27(2):305-8. . Mouton JW, Endtz HP, den Hollander JG, et al. In-vitro activity of quinupristin/dalfopristin

2014 eMedicine.com

99. Cellulitis (Follow-up)

IV q6-8h Meropenem 1 g IV q8h Ertapenem 1 g IV qd Cefotaxime 2 g IV q6h plus metronidazole 500 mg IV q6h or clindamycin 600-900 mg/kg IV q8h The following are first-line treatments in managing adult S aureus (MSSA) infections [ ] : Nafcillin (for patients with severe penicillin hypersensitivity: vancomycin, linezolid, quinupristin-dalfopristin, or daptomycin; add an appropriate agent in the presence of [or if there is a suspicion of] staphylococcal infection) or oxacillin 1-2 IV q4h Cefazolin 1 g (...) IV q8h Clindamycin 600-900 mg/kg IV q8h (may have cross-resistance and emergence resistance in erythromycin-resistant strains; induces resistance in MRSA) First-line agents in managing severe adult streptococcal infection are penicillin 2-4 MU IV every 4-6 hours plus clindamycin 600-900 mg/kg IV every 8 hours. [ ] For patients with severe penicillin hypersensitivity, use vancomycin, linezolid, quinupristin-dalfopristin, or daptomycin. Add an appropriate agent if a staphylococcal infection

2014 eMedicine.com

100. Cellulitis (Follow-up)

IV q6-8h Meropenem 1 g IV q8h Ertapenem 1 g IV qd Cefotaxime 2 g IV q6h plus metronidazole 500 mg IV q6h or clindamycin 600-900 mg/kg IV q8h The following are first-line treatments in managing adult S aureus (MSSA) infections [ ] : Nafcillin (for patients with severe penicillin hypersensitivity: vancomycin, linezolid, quinupristin-dalfopristin, or daptomycin; add an appropriate agent in the presence of [or if there is a suspicion of] staphylococcal infection) or oxacillin 1-2 IV q4h Cefazolin 1 g (...) IV q8h Clindamycin 600-900 mg/kg IV q8h (may have cross-resistance and emergence resistance in erythromycin-resistant strains; induces resistance in MRSA) First-line agents in managing severe adult streptococcal infection are penicillin 2-4 MU IV every 4-6 hours plus clindamycin 600-900 mg/kg IV every 8 hours. [ ] For patients with severe penicillin hypersensitivity, use vancomycin, linezolid, quinupristin-dalfopristin, or daptomycin. Add an appropriate agent if a staphylococcal infection

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>